1. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma 
Michael E. Wechsler, MD, Michel Laviolette, MD, Adalberto S. Rubin, MD, Jussara Fiterman, MD, Jose R. Lapa e Silva, MD, Pallav L. Shah, MD, Elie Fiss, MD, Ronald Olivenstein, MD, Neil C. Thomson, MD, Robert M. Niven, MD, Ian D. Pavord, MD, Michael Simoff, MD, Jeff B. Hales, MD, Charlene McEvoy, MD, Dirk-Jan Slebos, MD, Mark Holmes, MD, Martin J. Phillips, MD, Serpil C. Erzurum, MD, Nicola A. Hanania, MD, Kaharu Sumino, MD, Monica Kraft, MD, Gerard Cox, MB, Daniel H. Sterman, MD, Kyle Hogarth, MD, Joel N. Kline, MD, Adel H. Mansur, MD, Brian E. Louie, MD, William M. Leeds, MD, Richard G. Barbers, MD, John H.M. Austin, MD, Narinder S. Shargill, PhD, John Quiring, PhD, Brian Armstrong, MS, Mario Castro, MD 
Journal of Allergy and Clinical Immunology 
Volume 132, Issue 6, Pages e3 (December 2013)
DOI: /j.jaci
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Severe exacerbations and ED visits in the 5 years after BT. A, Proportion of subjects with severe exacerbations. B, Severe exacerbation rates. C, Proportion of subjects with ED visits for respiratory symptoms. D, ED visit rates. Values are point estimates with 95% upper and lower CIs. The 365-day period constituting year 1 began at 6 weeks after the last BT bronchoscopy.
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Prebronchodilator and postbronchodilator FEV1 over 5 years (percent predicted). Percent predicted prebronchodilator and postbronchodilator FEV1 values (means ± SEMs) for subjects completing follow-up during each year. The percent predicted prebronchodilator FEV1 values remained unchanged over the 5 years after BT. Postbronchodilator FEV1 remained higher at all times; increase in percent predicted FEV1 at baseline of 8.2% and at 5 years of 5.9%. BD, Bronchodilator.
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig E1
Annualized severe exacerbation rates (left panel) and ED visit rates (right panel) in the AIR2 trial over the 5-year evaluation period. The data for year 1 in these figures for both the sham (white bars) and BT (blue bars) groups are standardized to 52 weeks. The solid bars in both graphs represent the posttreatment period, and the hashed bars represent the treatment period.
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions